Managing Insomnia in Patients Prescribed Opioids

Introduction to Insomnia Management

The American Academy of Sleep Medicine recommends starting Cognitive Behavioral Therapy for Insomnia (CBT-I) immediately as first-line treatment for patients with insomnia, including those prescribed opioids like Norco, and if pharmacotherapy is needed, using short-acting benzodiazepine receptor agonists like zolpidem or ramelteon 1, 2, 3

CBT-I must be initiated before or alongside any sleep medication, as it provides superior long-term outcomes compared to pharmacotherapy alone, according to the American Academy of Sleep Medicine 1, 2, 4
Core CBT-I components to implement include stimulus control therapy, sleep restriction therapy, cognitive restructuring, and sleep hygiene education, as recommended by the American Academy of Sleep Medicine 1, 4, 3

If CBT-I alone is insufficient after 4-8 weeks, add pharmacotherapy as a supplement, using the algorithm recommended by the American Academy of Sleep Medicine, which includes zolpidem 10 mg, zaleplon 10 mg, or ramelteon 8 mg for sleep onset difficulty, and eszopiclone 2-3 mg or low-dose doxepin 3-6 mg for sleep maintenance difficulty 1, 5, 6, 3
The American Academy of Sleep Medicine recommends using the lowest effective dose for the shortest duration possible, typically 4-5 weeks for acute insomnia, and reassessing after 1-2 weeks to evaluate efficacy and side effects 1, 6, 4

The American Academy of Sleep Medicine recommends avoiding over-the-counter antihistamines, trazodone, atypical antipsychotics, long-acting benzodiazepines, and barbiturates for primary insomnia in patients on Norco, due to lack of efficacy, safety concerns, and potential for adverse effects 1, 3, 5, 6

Combining benzodiazepines with opioids significantly increases respiratory depression risk, and the American Academy of Sleep Medicine recommends preferring non-benzodiazepine options like ramelteon, low-dose doxepin, or zaleplon, which have minimal respiratory depression risk 3, 6
Ramelteon is the safest choice for patients with substance use history, as it is non-DEA scheduled and has zero abuse potential, according to the American Academy of Sleep Medicine 3, 6

Before prescribing any sleep medication, educate patients about treatment goals, realistic expectations, safety concerns, potential side effects, and drug interactions, as well as the importance of behavioral treatments and the risk of tolerance and rebound insomnia, as recommended by the American Academy of Sleep Medicine 1, 5, 3, 6

Follow-up every 2-4 weeks initially to assess effectiveness, side effects, and need for ongoing medication, and reassess after 4-5 weeks to determine if continued pharmacotherapy is necessary, as recommended by the American Academy of Sleep Medicine and the American Academy of Sleep Medicine 1, 5, 6, 4
Taper medications when conditions allow, facilitated by ongoing CBT-I, and screen for new or worsening comorbid conditions, such as depression, anxiety, or substance use disorder, as recommended by the American Academy of Sleep Medicine 1, 5